BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 20866043)

  • 1. Consumption of S-allylcysteine inhibits the growth of human non-small-cell lung carcinoma in a mouse xenograft model.
    Tang FY; Chiang EP; Pai MH
    J Agric Food Chem; 2010 Oct; 58(20):11156-64. PubMed ID: 20866043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-Allylcysteine inhibits tumour progression and the epithelial-mesenchymal transition in a mouse xenograft model of oral cancer.
    Pai MH; Kuo YH; Chiang EP; Tang FY
    Br J Nutr; 2012 Jul; 108(1):28-38. PubMed ID: 22011514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.
    Weng MC; Li MH; Chung JG; Liu YC; Wu JY; Hsu FT; Wang HE
    Biomed Pharmacother; 2019 Aug; 116():109032. PubMed ID: 31163381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.
    Zhou B; Wang D; Sun G; Mei F; Cui Y; Xu H
    Cell Physiol Biochem; 2018; 46(3):999-1008. PubMed ID: 29669316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
    Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
    Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
    Ye YT; Zhong W; Sun P; Wang D; Wang C; Hu LM; Qian JQ
    J Ethnopharmacol; 2017 Mar; 200():107-116. PubMed ID: 28088493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diallyl trisulfide induces apoptosis and inhibits proliferation of A549 cells in vitro and in vivo.
    Li W; Tian H; Li L; Li S; Yue W; Chen Z; Qi L; Hu W; Zhu Y; Hao B; Gao C; Si L; Gao F
    Acta Biochim Biophys Sin (Shanghai); 2012 Jul; 44(7):577-83. PubMed ID: 22595511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies.
    Xue X; Sun DF; Sun CC; Liu HP; Yue B; Zhao CR; Lou HX; Qu XJ
    Lung Cancer; 2012 Jun; 76(3):300-8. PubMed ID: 22261315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
    Lee H; Kim SJ; Jung KH; Son MK; Yan HH; Hong S; Hong SS
    Oncol Rep; 2013 Aug; 30(2):863-9. PubMed ID: 23708425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
    Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
    Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
    Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
    Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
    Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
    Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.
    Yang Y; Liu L; Zhang Y; Guan H; Wu J; Zhu X; Yuan J; Li M
    Int J Cancer; 2014 Oct; 135(7):1531-42. PubMed ID: 24550137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
    Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
    Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
    Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
    Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
    Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
    Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway.
    Zhou X; Zhou R; Li Q; Jie X; Hong J; Zong Y; Dong X; Zhang S; Li Z; Wu G
    Anticancer Drugs; 2019 Mar; 30(3):241-250. PubMed ID: 30640793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinnamtannin D1 from Rhododendron formosanum Induces Autophagy via the Inhibition of Akt/mTOR and Activation of ERK1/2 in Non-Small-Cell Lung Carcinoma Cells.
    Way TD; Tsai SJ; Wang CM; Jhan YL; Ho CT; Chou CH
    J Agric Food Chem; 2015 Dec; 63(48):10407-17. PubMed ID: 26567590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.